23 May 2012, BioSpectrum Bureau , BioSpectrum
Singapore: Pfizer named Mr Olivier Brandicourt as president and general manager of the Emerging Markets and Established Products Business Units, effective June 1, 2012. He will succeed David Simmons, who is leaving Pfizer to become the chairman and CEO of Pharmaceutical Product Development, a privately held global contract research organization.
"Olivier is ideally suited to take on this new role," said Ian Read, chairman and CEO, Pfizer. "He has more than 20 years of global experience in the pharmaceutical industry. Olivier is both a physician and proven business leader who understands the many challenges of today's changing industry and healthcare landscape."
Dr Brandicourt has held senior positions at Pfizer across a range of disciplines, including medical and marketing, as well as country and regional management roles in Latin America, Europe, Canada, the UK and the US. Most recently, he served as president and general manager of the Primary Care Business Unit and is a member of the Pfizer executive leadership team. He is an honorary fellow of the Royal College of Physicians in London and a trustee of the Children's Aid Society of New York.
Mr John Young, currently Regional President of Europe and Canada for the Primary Care business, is appointed President and General Manager of the Primary Care Business Unit and will join the company's executive leadership team, effective June 1, 2012. Over his 25-year career with Pfizer, Mr. Young has held a number of commercial positions with the company, including country and regional management roles in Australia, New Zealand and the UK.